arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Vera Therapeutics, Inc.

VERA
$33.03 ▼ -3.20 (-8.82%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Weak
Neutral
auto_awesome

Analytical Summary

Vera Therapeutics, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.4B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -18.4%
FCF / Share $-1.40
Trailing P/E
Price / Book 5.8x
FCF Yield
Debt / Equity 0.18
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-121.03M
↓ -134.1%
FCF / Share Free cash flow per share
$-1.40
↑ +6.4%
Long-Term Debt Long-term obligations
$75.23M
— +0.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Financial Health
49
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters